← back to search

Shalini Shenoy

South Asian University · US
Area of research
Organic Chemistry · Hematology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Antibiotic Resistance in Bacteria, Synthesis and biological activity, and Antimicrobial Resistance in Staphylococcus.
h-index
32
citations
4,248
works
230
NIH funding
primary concept
Medicine
email

Recent publications

Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation
Blood 2025cited by 3position: middledoi
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Nature 2023cited by 450position: middledoi
Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium
The Lancet 2023cited by 110position: middledoi
The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with <i>KMT2A</i>-Rearranged or <i>NPM1</i> Mutant AML: Updated Results of a Phase (Ph) 1 Study
Blood 2022cited by 34position: middledoi
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Journal of Clinical Oncology 2021cited by 242position: middledoi
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation
Blood Advances 2021cited by 32position: middledoi
The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)
Journal of Allergy and Clinical Immunology 2018cited by 83position: middledoi
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis
Biology of Blood and Marrow Transplantation 2017cited by 57position: middledoi
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita
Biology of Blood and Marrow Transplantation 2013cited by 129position: middledoi
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
Blood 2012cited by 344position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Eytan M. Stein · The University of Texas MD Anderson Cancer Center2 papers (2022–2023)Richard M. Stone · Harvard University2 papers (2022–2023)David S. Dickens · University of Iowa Stead Family Children’s Hospital2 papers (2022–2023) · 2 papers (2022–2023)Rebecca G. Bagley · Kala Pharmaceuticals (United States)2 papers (2022–2023)Manish R. Patel · Centers for Disease Control and Prevention2 papers (2022–2023)Martha Arellano · Emory University2 papers (2022–2023) · 2 papers (2022–2023)Neerav Shukla · AbbVie (United States)2 papers (2022–2023) · 2 papers (2022–2023)Gerard M. McGeehan · Eloxx Pharmaceuticals (United States)2 papers (2022–2023)Michael J. Thirman · University of Chicago Medical Center2 papers (2022–2023)Ibrahim Aldoss · City of Hope2 papers (2022–2023)Branko Cuglievan · The University of Texas MD Anderson Cancer Center2 papers (2022–2023)John F. DiPersio · Bluebird Bio (United States)2 papers (2022–2023) · 1 papers (2012–2012)David A. Jacobsohn · National Hospital1 papers (2021–2021)Florian Perner · Universitätsmedizin Greifswald1 papers (2023–2023)Tillmann Taube · Charité - Universitätsmedizin Berlin1 papers (2012–2012)Ugo Ramenghi · Azienda Ospedaliera Citta' della Salute e della Scienza di Torino1 papers (2012–2012)